Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
We studied expression of Flt-1 and Flk-1 receptors on tumor cells obtained from 83 patients with locally advanced breast cancer after neoadjuvant chemotherapy. The mean period of observations was 32.3 months. The median recurrence-free survival periods for Flt-1+ and Flt-1- patients were 55 and 32 months, respectively (p=0.0064). The overall survival periods for Flt-1- and Flt-1+ patients were 45 and 67.6 months, respectively (p=0.014). The mean recurrence-free survival periods for Flk-1+ and Flk-1- patients were 40.8 and 60.9 months, respectively (p=0.035). Expression of VEGF had no prognostic value. Our results show that overexpression of Flk-1 on breast cancer cells in patients receiving neoadjuvant chemotherapy is associated with a poor prognosis. By contrast, overexpression of Flt-1 improves survival.
- J. S. de Jong, P. J. van Diest, P. van der Valk, and J. P. Baak, J. Pathol., 184,No. 1, 44-52 (1998).
- M. Decaussin, H. Sartelet, C. Robert, et al., Ibid., 188,No. 4, 369-377 (1999).
- B. A. Fine, P. T. Valente, G. I. Feinstein, and T. Dey, Gynecol. Oncol., 76,No. 1, 33-39 (2000).
- C. Herold-Mende, T. Andl, F. Laemmler, et al., HNO, 47,No. 8, 706-711 (1999).
- Masabumi Shibuya, Int. J. Biochem. Cell Biol., 33,No. 4, 409-420 (2001).
- Y. Yao, T. Kubota, K. Sato, et al., Acta Neurochir., 143, 159-166 (2001).
- H. Yoshiji, D. E. Gomez, M. Shibuya, and U. P. Thorgeirsson, Cancer Res., 56,No. 9, 2013-2016 (1996).
- Expression of Flt-1 and Flk-1 Receptors for Vascular Endothelial Growth Factor on Tumor Cells as a New Prognostic Criterion for Locally Advanced Breast Cancer
Bulletin of Experimental Biology and Medicine
Volume 135, Issue 5 , pp 478-481
- Cover Date
- Print ISSN
- Online ISSN
- Kluwer Academic Publishers-Plenum Publishers
- Additional Links
- breast cancer
- VEGF, Flt-1, Flk-1
- Industry Sectors